Dernières nouvelles pour Brainstorm Cell (NASDAQ:BCLI) Stock

Brainstorm Cell

Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Brainstorm Cell Therapeutics Inc

WIIM

BCLI

BrainStorm Cell Therapeutics is trading lower after receiving a delisting notice from Nasdaq effective July 18, 2025.

BrainStorm Cell Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares crashed 42.74% to $0.67 in after-hours trading on Friday after the company announced its voluntary delisting from the Nasdaq Capital Market.
Check out <a href="https://www.benzinga.com/quote/BCLI">how BCLI stock is trading here</a>.
What Happened: The biotechnology firm received formal notification from The Nasdaq Stock Market LLC that its common stock will be suspended from trading at market open on Friday. 
The delisting stems from non-compliance with Nasdaq Listing Rule 5550(b)(1), which requires maintaining minimum shareholder equity.
BrainStorm&#8217;s stock has declined 45.33% year-to-date, closing Thursday at $1.17 before the after-hours selloff. The company has secured approval to trade on the OTCQB Venture Market under the same BCLI ticker symbol, effective Friday.
&#8220;While this delisting from Nasdaq is a challenging outcome, we want to assure our shareholders and the patient community that it does not alter our core mission,&#8221; said CEO Chaim Lebovits in a statement. The company emphasized its continued focus on developing NurOwn, its lead investigational therapy for amyotrophic lateral sclerosis (ALS).
See Also: <a href="https://benzinga.com/crypto/25/07/46484730/bitcoin-ethereum-dogecoin-rise-as-crucial-crypto-bills-sail-through-the-us-house-analytics-firm-sees-20-25-upside-for-btc-before-profit-taking-kicks-in">Bitcoin, Ethereum, Dogecoin Rise As Crucial Crypto Bills Sail Through The US House: Analytics Firm Sees 20%-25% Upside For BTC Before Profit-Taking Kicks In</a>
CEO of BrainStorm Cell Therapeutics, Chaim Lebovits, on the company&#8217;s delisting stated, &#8220;While this delisting from NASDAQ is a challenging outcome, we want to assure our shareholders and the patient community that it does not alter our core mission or our unwavering commitment to advancing NurOwn for ALS patients.&#8221;
Why It Matters: BrainStorm develops autologous adult stem cell therapies for neurodegenerative diseases. Its proprietary NurOwn platform uses mesenchymal stem cells to produce neurotrophic factor-secreting cells designed to treat ALS patients. The therapy has received Orphan Drug designation from both the FDA and European Medicines Agency.
The company completed a Phase 3 ALS trial and plans to launch a Phase 3b trial under a Special Protocol Assessment agreement with the FDA. BrainStorm also conducted a Phase 2 trial for progressive multiple sclerosis, supported by a National MS Society grant.
The delisting does not impact business operations or research programs, according to the company. 
Benzinga's Edge Stock Rankings indicate BrainStorm Cell Therapeutics has a positive short-term price trend. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">Track the performance of other players</a> in this segment.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="862" height="148" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18030651/Screenshot-2025-07-18-123631.png" alt="" class="wp-image-990878" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18030651/Screenshot-2025-07-18-123631.png 862w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18030651/Screenshot-2025-07-18-123631-300x52.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18030651/Screenshot-2025-07-18-123631-768x132.png 768w" sizes="(max-width: 862px) 100vw, 862px" /></a></figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://benzinga.com/news/25/07/46458290/cathie-woods-ethereum-double-down-ark-bets-7-9-million-on-eth-staking-etf-buy-while-selling-coinbase-at-highs">Cathie Wood&#8217;s Ethereum Double-Down: Ark Bets $7.9 Million On ETH-Staking ETF Buy While Selling Coinbase At Highs</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shutterstock

Biotech

Equities

News

Health Care

Events

After-Hours Center

Markets

Media

General

Brainstorm Cell Therapeutics Crashes 42% After Voluntary Nasdaq Delisting Announcement

<h3>Gainers</h3>
<ul>
<li>Telomir Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) stock increased by 52.1% to $1.84 during Thursday's after-market session. The market value of their outstanding shares is at $34.2 million. </li>
<li>VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) shares increased by 6.77% to $1.26. The company's market cap stands at $20.9 million. </li>
<li>Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) shares moved upwards by 6.45% to $12.87. The market value of their outstanding shares is at $949.5 million. </li>
<li>Synlogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYBX#NASDAQ">SYBX</a>) stock moved upwards by 6.02% to $1.76. The market value of their outstanding shares is at $17.6 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) stock moved upwards by 5.33% to $0.63. The market value of their outstanding shares is at $1.3 million. </li>
<li>TAO Synergies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOX#NASDAQ">TAOX</a>) shares increased by 5.21% to $9.89. The market value of their outstanding shares is at $12.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock decreased by 49.6% to $0.59 during Thursday's after-market session. The company's market cap stands at $11.8 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares decreased by 8.68% to $2.21. The company's market cap stands at $4.4 million. </li>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) shares fell 7.44% to $3.31. The market value of their outstanding shares is at $5.9 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock declined by 6.58% to $0.36. The company's market cap stands at $16.5 million. </li>
<li>Vivani Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VANI#NASDAQ">VANI</a>) shares fell 5.67% to $1.5. The market value of their outstanding shares is at $95.9 million. </li>
<li>Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) shares declined by 5.29% to $0.81. The company's market cap stands at $77.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

NRIX

PSTV

RDHL

SLRX

SNOA

SYBX

TAOX

TELO

VANI

VRCA

VYNE

12 Health Care Stocks Moving In Thursday's After-Market Session

BrainStorm Cell Therapeutics Receives Delisting Notice From Nasdaq Effective On July 18, 2025.

BrainStorm Cell Therapeutics Acknowledges FDA Consideration Of Citizen Petition Requesting New Review Of Data Supporting NurOwn; Says Will Continue With Planned Phase 3b Trial

<a href="https://www.sec.gov/Archives/edgar/data/1137883/000110465925062607/tm2518806d1_s3.htm">https://www.sec.gov/Archives/edgar/data/1137883/000110465925062607/tm2518806d1_s3.htm</a>

Offerings

Brainstorm Cell Therapeutics Files Prospectus For Offer & Sale Of Up To 2.8M Shares Of Common Stock By Selling Stockholder

Key findings include:
<ul>
<li>90% of participants (9/10) survived more than five years from the onset of ALS symptoms, compared to published estimates indicating that approximately 10% of individuals with ALS survive beyond five years. Notably, the single death in the cohort occurred following elective euthanasia.</li>
<li>The median survival observed in the EAP cohort was 6.8 years (range: 6 to 7 years) from symptom onset.</li>
<li>Given that approximately 10% of individuals with ALS survive beyond five years[1], the probability of observing such extended survival in 9 out of 10 participants purely by chance is extremely low. This strongly suggests that the survival outcomes in this cohort are unlikely to be the result of random variation alone.</li>
</ul>

BrainStorm Announces New Survival Data From Expanded Access Program Of NurOwn In ALS; 90% Of Participants Survived More Than Five Yers From Onset Of ALS Symptoms

BrainStorm Secures Strategic U.S. Manufacturing Deal With Minaris For Phase 3b ALS Trial Production

<h3>Gainers</h3>
<ul>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares moved upwards by 55.5% to $4.76 during Wednesday's after-market session. The market value of their outstanding shares is at $4.7 million. </li>
<li>SAB Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABS#NASDAQ">SABS</a>) shares moved upwards by 15.94% to $2.0. The market value of their outstanding shares is at $18.5 million. </li>
<li>AEON Biopharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AEON#AMEX">AEON</a>) stock rose 9.3% to $0.53. The market value of their outstanding shares is at $6.0 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) shares rose 7.26% to $3.1. The company's market cap stands at $13.8 million. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock moved upwards by 7.2% to $1.99. The market value of their outstanding shares is at $2.9 million. </li>
<li>Immutep (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMP#NASDAQ">IMMP</a>) stock moved upwards by 6.7% to $2.07. The market value of their outstanding shares is at $301.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) shares decreased by 37.0% to $0.04 during Wednesday's after-market session. As per the news, the Q1 earnings report came out 4 days ago. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock declined by 20.4% to $3.59. The company's market cap stands at $326.8 million. The company's, Q2 earnings came out 4 days ago. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares decreased by 12.72% to $1.03. The market value of their outstanding shares is at $5.8 million. As per the news, the Q1 earnings report came out 4 days ago. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock fell 12.26% to $0.27. The company's market cap stands at $2.9 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) stock decreased by 7.02% to $0.36. The market value of their outstanding shares is at $21.0 million. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares decreased by 6.76% to $0.37. The market value of their outstanding shares is at $53.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEON

BCAB

BDSX

BJDX

IMMP

LIPO

PTPI

SABS

VTAK

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares moved upwards by 56.6% to $1.77 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.0 million. The company's, Q1 earnings came out yesterday. </li>
<li>Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) shares increased by 30.17% to $22.0. The company's market cap stands at $144.3 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 27.47% to $0.01. </li>
<li>Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) stock moved upwards by 25.23% to $1.34. The market value of their outstanding shares is at $22.2 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock rose 24.84% to $0.28. The market value of their outstanding shares is at $5.1 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock increased by 14.48% to $403.0. The company's market cap stands at $5.2 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock fell 20.7% to $8.8 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.1 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares fell 19.6% to $0.33. The company's market cap stands at $1.5 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock decreased by 18.16% to $0.27. The company's market cap stands at $7.8 million. </li>
<li>Lyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) stock decreased by 13.1% to $0.09. The company's market cap stands at $6.1 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock decreased by 11.03% to $1.21. The company's market cap stands at $6.9 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock declined by 10.45% to $0.3. The market value of their outstanding shares is at $1.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIAF

EKSO

ENTO

EYEN

HCTI

IRIX

LYRA

PTIX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 110.1% to $0.02 during Monday's pre-market session. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock rose 78.48% to $5.41. The market value of their outstanding shares is at $2.9 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock rose 41.66% to $1.87. The company's market cap stands at $10.6 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock increased by 34.84% to $0.01. </li>
<li>Armata Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMP#AMEX">ARMP</a>) stock increased by 32.59% to $1.79. The company's market cap stands at $64.7 million. The company's, Q1 earnings came out 3 days ago. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares moved upwards by 25.04% to $1.5. The market value of their outstanding shares is at $20.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mainz Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNZ#NASDAQ">MYNZ</a>) shares decreased by 17.6% to $2.01 during Monday's pre-market session. The market value of their outstanding shares is at $4.4 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) stock fell 14.78% to $6.69. The market value of their outstanding shares is at $44.0 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>I-MAB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMAB#NASDAQ">IMAB</a>) stock fell 11.12% to $0.8. The company's market cap stands at $64.7 million. The company's, H1 earnings came out 2 days ago. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) shares decreased by 10.51% to $4.09. The market value of their outstanding shares is at $22.4 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) stock fell 8.78% to $3.64. The market value of their outstanding shares is at $19.4 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock decreased by 7.89% to $0.21. The company's market cap stands at $5.8 million. As per the news, the Q1 earnings report came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARMP

FBRX

IMAB

KLTO

LPCN

MYNZ

PLRZ

STSS

SXTC

12 Health Care Stocks Moving In Monday's Pre-Market Session

BCLI: 120% &#x7C; <a href="https://www.benzinga.com//node/45489890">BrainStorm Cell Therapeutics shares are trading higher after the company received FDA clearance to initiate its Phase 3b trial of NurOwn for the treatment of ALS.</a>
&nbsp;
NVAX: 28% &#x7C; <a href="https://www.benzinga.com//node/45488265">Novavax Wins Limited FDA Nod For COVID Shot—Cleared Only For Seniors, High-Risk Groups Amid Safety Scrutiny</a>
&nbsp;
SOC: 18% &#x7C; <a href="https://www.benzinga.com//node/45489188">Sable Offshore Ramps Up Oil Production, Raises 2H25 Output Guidance to 40K–50K BOE/Day</a>

Trading Ideas

NVAX

Market-Moving News for May 19th

BrainStorm Cell Therapeutics shares are trading higher after the company received FDA clearance to initiate its Phase 3b trial of NurOwn for the treatment of ALS.

BrainStorm Receives FDA Clearance To Initiate Its Phase 3b Trial Of NurOwn For Treatment Of ALS

Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.97) by 53.61 percent. This is a 40 percent increase over losses of $(0.75) per share from the same period last year.

Earnings

Earnings Beats

Brainstorm Cell Q1 EPS $(0.45) Beats $(0.97) Estimate

ACOG

AENT

AIRI

AMAT

AREN

BABA

BEKE

BFRI

BHST

BIRK

BLIN

BNZI

BRAG

BTBT

BTDR

CAVA

CSIQ

CYCC

DFLI

DOCS

DTIL

DTST

DUOT

EDAP

EDBL

FLNT

FTLF

GAMB

GAME

GLOB

GORV

GOSS

GSX Techedu Inc. American Depositary Shares

GOTU

HAFN

IMCC

INKT

IVVD

JAGX

KORE

KPLT

KULR

LFWD

LGCY

LMFA

LPTH

LTRN

MITQ

MRSN

NICE

NRXP

NTES

NVVE

NXPL

OMER

ONDS

ORGN

PAVM

PHGE

PIII

PLBY

POCI

PPSI

PVLA

QUBT

RIME

RNXT

ROLR

SANW

SCWO

SIDU

SNYR

SOBO

SPCE

SRTS

SRXH

SWKH

TIVC

TLSI

TRAK

TSHA

TSSI

Earnings Scheduled For May 15, 2025

<h3>Gainers</h3>
<ul>
<li>Regulus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) shares increased by 132.5% to $7.83 during Wednesday's regular session. The company's market cap stands at $519.0 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock increased by 71.13% to $54.08. The company's market cap stands at $703.7 million. </li>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) shares increased by 62.72% to $2.62. The company's market cap stands at $12.9 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) shares moved upwards by 30.18% to $6.9. The market value of their outstanding shares is at $334.8 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) stock increased by 24.26% to $7.06. The company's market cap stands at $78.3 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock rose 20.73% to $1.31. The market value of their outstanding shares is at $7.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>GeneDx Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGS#NASDAQ">WGS</a>) stock declined by 38.7% to $71.69 during Wednesday's regular session. The company's market cap stands at $2.0 billion. As per the news, the Q1 earnings report came out today. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock decreased by 23.59% to $2.83. The company's market cap stands at $2.3 million. </li>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) stock declined by 21.78% to $7.76. The market value of their outstanding shares is at $25.1 million. </li>
<li>Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) stock fell 21.53% to $1.75. The market value of their outstanding shares is at $52.8 million. The company's, Q1 earnings came out yesterday. </li>
<li>Immunic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMUX#NASDAQ">IMUX</a>) shares decreased by 15.63% to $1.08. The company's market cap stands at $103.4 million. </li>
<li>Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) shares fell 15.54% to $0.25. The market value of their outstanding shares is at $11.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABEO

CLRB

COEP

IMUX

NAOV

NTRB

RGLS

ZYXI

12 Health Care Stocks Moving In Wednesday's Intraday Session

New findings highlight impact of UNC13A genotype on treatment response in ALS

BrainStorm To Present Pharmacogenomic Data On NurOwn At ISCT 2025, Highlighting UNC13A Genotype In Amyotrophic Lateral Sclerosis

<h3>Gainers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares increased by 34.5% to $0.01 during Monday's regular session. </li>
<li>CG Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) shares moved upwards by 32.81% to $29.71. The market value of their outstanding shares is at $2.2 billion. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) stock rose 32.18% to $13.8. The company's market cap stands at $654.0 million. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) shares moved upwards by 30.56% to $1.2. The company's market cap stands at $11.8 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) shares increased by 24.21% to $2.36. The company's market cap stands at $22.2 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) shares moved upwards by 24.0% to $1.21. The company's market cap stands at $6.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares fell 26.2% to $0.1 during Monday's regular session. The company's market cap stands at $3.9 million. </li>
<li>SILO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) stock fell 22.6% to $0.89. The company's market cap stands at $3.9 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares decreased by 20.8% to $3.96. The market value of their outstanding shares is at $102.9 million. </li>
<li>Abpro Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABP#NASDAQ">ABP</a>) stock fell 18.94% to $0.26. The market value of their outstanding shares is at $13.4 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares decreased by 18.74% to $0.15. The company's market cap stands at $6.7 million. </li>
<li>Protara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARA#NASDAQ">TARA</a>) stock declined by 18.52% to $3.52. The company's market cap stands at $129.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CGON

GELS

IBIO

LGMK

SILO

SNTI

SPRB

TARA

ZYBT

12 Health Care Stocks Moving In Monday's Intraday Session

Small Cap

Press Releases

BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting

BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit

BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025

BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19

BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn®

FDA Review of Citizen Petition Offers a Fresh Look at NurOwn®'s Evidence of Treatment Effectiveness

Comments

Brainstorm Cell

Actualités

Dernières nouvelles pour Brainstorm Cell (NASDAQ:BCLI) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL